Corcept therapeutics officer Guyer sells $7350 in shares

William Guyer, Chief Development Officer at Corcept Therapeutics Inc (NASDAQ:CORT), sold 100 shares of common stock on July 1, 2025, at a price of $73.505, for a total value of $7350. The transaction comes as Corcept, with a market capitalization of $7.66 billion, has delivered an impressive 137% return over the past year and maintains a "GREAT" financial health score according to InvestingPro analysis.

On the same day, Guyer also exercised options to acquire 100 shares of Corcept Therapeutics at an exercise price of $21.65, for a total value of $2165. Following the transaction, Guyer directly owns 5487 shares of Corcept Therapeutics. The stock, currently trading near Fair Value based on InvestingPro models, commands a premium valuation with a P/E ratio of 56.25, reflecting strong market confidence in the company’s growth prospects.

The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

Fully exercisable.

In other recent news, Corcept Therapeutics announced significant results from its CATALYST trial, which demonstrated that its drug Korlym significantly improved glucose control in patients with hypercortisolism and difficult-to-control type 2 diabetes. The trial showed a notable reduction in hemoglobin A1c levels and weight in patients receiving the treatment. Additionally, the company presented favorable results from its Phase 3 ROSELLA trial, which evaluated relacorilant in combination with nab-paclitaxel for treating platinum-resistant ovarian cancer. This study met its primary endpoint, showing a 30% reduction in the risk of disease progression compared to monotherapy, with an improvement in overall survival.

H.C. Wainwright reaffirmed its Buy rating and $145 price target for Corcept, emphasizing the potential impact of these findings on the company’s stock valuation. Similarly, Truist Securities reiterated its Buy rating and $135 price target, highlighting the significant opportunity for Corcept in treating hypercortisolism with co-morbid diabetes. In corporate governance news, Corcept’s recent annual stockholder meeting saw the election of nine directors and the ratification of Ernst & Young LLP as the company’s independent accounting firm. The meeting outcomes were disclosed in a recent SEC filing, ensuring transparency for shareholders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.